Tag: Cancer Therapy
-
BioLineRx Wins USPTO Allowance for GLIX1 Cancer Therapy Patent
BioLineRx Announces USPTO Notice of Allowance for GLIX1 Patent BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent covering the company’s GLIX1 program. This milestone strengthens the intellectual property framework around GLIX1, a molecule aimed at treating a broad range of cancers.…
-
BioLineRx GLIX1 Patent Receipt: USPTO Notice of Allowance Expands Cancer Treatment Reach
BioLineRx Secures USPTO Notice of Allowance for GLIX1 Patent BioLineRx announced a pivotal milestone: the U.S. Patent and Trademark Office has issued a Notice of Allowance for the GLIX1 patent, covering its use in treating a broad spectrum of cancers. This development marks a significant step in protecting the company’s GLIX1-based therapeutic approach as it…
-
BioLineRx Wins USPTO Notice of Allowance for GLIX1 Cancer Therapy Patent Across Most Cancers
Overview: A Major Step Forward for GLIX1 BioLineRx announced a significant milestone in its cancer therapy program with a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its key patent covering GLIX1. This development marks an important expansion of protection for GLIX1 as a potential treatment for a broad range…
-
Immunotherapy Advances in SCLC: Promise, Limits, and the Biomarker Challenge
Current gains from immunotherapy in small cell lung cancer (SCLC) Immunotherapy has altered the treatment landscape for SCLC, offering meaningful efficacy where options were once limited. Checkpoint inhibitors that unleash the body’s immune system to attack cancer cells have demonstrated survival benefits in certain patients and disease settings, particularly when used in first-line combinations or…
-
New Insights into Why Some Breast Cancers Resist Antibody-Drug Conjugates (ADCs) Therapy
Understanding ADCs and Why They Matter in Breast Cancer Antibody‑drug conjugates (ADCs) are a cutting‑edge class of cancer therapies designed to target malignant cells with precision. By pairing a cancer‑specific antibody with a potent cytotoxic drug, ADCs aim to destroy tumor cells while limiting damage to healthy tissue. In breast cancer, ADCs have shown promise,…
-
Why Some Breast Cancers Resist Antibody Drug Conjugates: New Mayo Clinic Insights
Understanding the Challenge: Breast Cancer and Antibody Drug Conjugates Antibody drug conjugates (ADCs) represent a promising class of targeted cancer therapies. They couple a cancer-seeking antibody with a potent cytotoxic drug, delivering treatment directly to tumor cells while aiming to spare healthy tissue. In breast cancer, these therapies have shown notable potential, especially for tumors…
-
HIV Research: A Catalyst for Breakthroughs Across Medicine
The Enduring Impact of HIV Research HIV/AIDS research has become more than a focused effort against a single disease. Over the past four decades, U.S.-funded HIV research has advanced science in ways that touch immunology, cancer therapy, vaccines, and global health at large. A recent Nature Medicine commentary by leading researchers highlights how this sustained…
-
Changing the Narrative: How Calgary’s iSARP Is Redefining Sarcoma Therapy
Changing the Narrative in Calgary’s Medical Landscape When Dr. Michael Monument returned to his hometown of Calgary in 2014 after a fellowship at the University of Utah, colleagues warned him that the city might not be the best place to pursue sarcoma research. Sarcoma, a relatively rare family of bone and soft tissue tumors that…
-
TIGIT Immune Checkpoint Promotes Tissue Healing and Regeneration
Overview: A new role for an immune checkpoint Immune checkpoint inhibitors have transformed cancer therapy by releasing the brakes on the immune system. A surprising new finding from researchers at the University of Zurich (UZH) reveals that one such brake, TIGIT, does more than help tumor-fighting immune cells—it also promotes tissue healing. This discovery could…
-
CancerVax Precision Therapy Demonstrates Liver-Sparing Potential in In-Vitro Tests
Breakthrough in Precision Cancer Therapy: Liver-Sparing in Early Studies Lehi, Utah — CancerVax, Inc., a pre-clinical biotechnology company, announced today that recent in-vitro studies demonstrate a significant reduction in liver toxicity for its universal cancer treatment platform. The findings address a long-standing challenge in oncology: protecting healthy liver tissue while delivering effective cancer-killing therapy. If…